Nevus, Pigmented  >>  TPI 287  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
TPI 287 / CNS Pharma
NCT01067066: A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma

Terminated
1
21
US
TPI 287, Temodar (Temozolomide), Temozolomide
M.D. Anderson Cancer Center, Cortice Biosciences, Inc.
Melanoma
07/16
07/16

Download Options